下肢外周动脉疾病血运重建患者入院前阿片类药物使用与结局
这项丹麦全国性回顾性注册研究纳入1996至2018年间首次因下肢外周动脉疾病接受血运重建的40 186例患者,按入院前阿片类药物使用情况分组,分析出院后结局。结果显示,当前新用户和长期用户一年全因死亡风险显著高于非用户,且许多既往使用者出院后继续用药。
要点
- 当前新用户一年全因死亡风险较非用户升高,调整后HR 1.64(95%CI 1.44-1.86)。
- 当前长期用户一年全因死亡风险亦升高,调整后HR 1.59(95%CI 1.46-1.74)。
- 长期用户出院后3个月内阿片类药物续方比例最高,达76.7%。
核心结论
- 血运重建前阿片类药物使用与较高的全因死亡率相关,可能反映更严重的疾病状态。
- 尽管进行了血运重建,许多有阿片类药物使用史的患者出院后仍继续用药,需谨慎处方和结构化随访。
研究设计与样本
- 丹麦全国性回顾性注册研究,纳入1996至2018年间首次接受血管内或外科血运重建的下肢外周动脉疾病患者。
- 共纳入40 186例血运重建后存活患者,中位年龄70岁,54%为男性。
- 根据入院前阿片类药物使用情况分为当前新用户、当前长期用户、近期用户、既往用户和非用户五组。
- 采用多变量Cox回归分析出院后结局。
主要发现
- 当前新用户占5.4%,当前长期用户占22.9%,近期用户占14.5%,既往用户占19.0%,非用户占38.2%。
- 阿片类药物使用者中表现为慢性肢体威胁性缺血的比例更高。
- 出院后3个月内阿片类药物续方比例在当前长期用户中最高(76.7%),在非用户中最低(14.6%)。
- 与非用户相比,一年调整后全因死亡风险比:当前新用户1.64(95%CI 1.44-1.86),当前长期用户1.59(95%CI 1.46-1.74),近期用户1.13(95%CI 1.03-1.26),既往用户无风险增加。
临床怎么用
- 对血运重建前有阿片类药物使用史的外周动脉疾病患者,应加强出院后疼痛管理和随访。
- 处方阿片类药物时需谨慎,并关注持续用药患者的复杂照护需求。
局限性
- 作为回顾性注册研究,无法确认阿片类药物使用与死亡率之间的因果关系。
- 阿片类药物使用与死亡率关联可能反映更严重的疾病状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This nationwide, retrospective, registry study aimed to evaluate the rate of continued opioid use after revascularisation in patients with lower extremity peripheral artery disease (PAD) and the association between opioid treatment and post-discharge mortality. METHODS: Using Danish national registries, all patients undergoing first time endovascular or surgical revascularisation for PAD (1996 - 2018) were identified. Patients were categorised based on opioid use before admission: current new users (first time opioid prescription within 30 days before admission); current long term users (opioid prescription both before and within 30 days before admission); recent users (prescription within 31 - 365 days before admission); former users (prescription more than one year before); and non-users (no history of opioid prescription). Outcomes post-discharge were analysed using multivariable Cox regression. RESULTS: Among 40 186 patients (median age 70 years, 54% men) surviving revascularisation, 5.4% were current new users, 22.9% current long term users, 14.5% recent users, 19.0% former users, and 38.2% non-users. A higher proportion of opioid users presented with chronic limb threatening ischaemia. Within three months post-discharge, opioid prescription refills were highest among current long term users (76.7%) and lowest among non-users (14.6%). Compared with non-users, the one year adjusted hazard ratio for all cause mortality was 1.64 (95% confidence interval [CI] 1.44 - 1.86) for current new users, 1.59 (95% CI 1.46 - 1.74) for current long term users, and 1.13 (95% CI 1.03 - 1.26) for recent users, with no increased risk for former users. CONCLUSION: This nationwide study identified a high risk subgroup of PAD patients with substantial opioid use and elevated mortality risk. Despite revascularisation, many with prior opioid use continued treatment post-discharge, highlighting the need for cautious prescribing and structured follow up to manage persistent pain and complex care needs. Although causality cannot be confirmed, pre-revascularisation opioid use was associated with a higher all cause mortality rate, probably reflecting greater disease severity.
引用
- Petersen JK, Bager LGV, Østergaard L, et al. Pre-admission Opioid Use and Associated Outcomes in Patients Revascularised for Lower Peripheral Artery Disease. Eur J Vasc Endovasc Surg. 2025. PMID: 40789544. doi:10.1016/j.ejvs.2025.08.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。